Early-Detection Sequencing Assays Prove Highly Specific.
Ultrasensitive DNA-sequencing methods proved more than 99% specific, according to initial findings from GRAIL's Circulating Cell-Free Genome Atlas Study. The data, presented at the American Association for Cancer Research Annual Meeting 2018, demonstrate the feasibility of designing a blood test for early cancer detection.